Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$1.56
+0.6%
$1.54
$0.87
$6.37
$154.99M0.86485,485 shs603,512 shs
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
$1.81
-12.1%
$2.30
$0.55
$49.00
$161.44M32.55 million shs365,870 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$13.44
+1.1%
$12.83
$7.09
$27.38
$167.30M0.45134,718 shs58,928 shs
Exicure, Inc. stock logo
XCUR
Exicure
$7.40
-2.6%
$7.82
$1.44
$36.00
$48.01M3.6788,227 shs40,456 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
+0.65%-3.11%+5.76%+52.20%-69.17%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-12.14%-12.14%-65.98%+113.70%+180,999,900.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+1.13%+4.11%+7.31%+20.21%+82.48%
Exicure, Inc. stock logo
XCUR
Exicure
-2.63%+11.61%+15.09%-25.78%+1,351.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alector, Inc. stock logo
ALEC
Alector
4.0623 of 5 stars
3.13.00.04.53.02.50.0
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
0.9661 of 5 stars
3.00.00.00.00.01.70.0
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.0752 of 5 stars
3.50.01.72.72.72.51.3
Exicure, Inc. stock logo
XCUR
Exicure
0.9047 of 5 stars
0.02.00.04.71.70.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.29
Hold$4.17167.09% Upside
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
2.00
Hold$3.0065.75% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50126.93% Upside
Exicure, Inc. stock logo
XCUR
Exicure
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest XCUR, ALEC, CTOR, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2025
Alector, Inc. stock logo
ALEC
Alector
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$2.50 ➝ $3.50
5/23/2025
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
5/23/2025
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/9/2025
Alector, Inc. stock logo
ALEC
Alector
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$100.56M1.55N/AN/A$1.29 per share1.21
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/A$0.64 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.85$0.89 per share15.07$2.05 per share6.56
Exicure, Inc. stock logo
XCUR
Exicure
$500K93.54N/AN/A$1.12 per share6.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/7/2025 (Estimated)
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/A0.00N/AN/A-53.88%-18.86%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6919.48N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Exicure, Inc. stock logo
XCUR
Exicure
-$9.70M-$3.82N/AN/AN/A-219.60%-82.03%8/12/2025 (Estimated)

Latest XCUR, ALEC, CTOR, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17N/AN/AN/A$57.93 millionN/A
8/7/2025Q2 2025
Alector, Inc. stock logo
ALEC
Alector
-$0.45N/AN/AN/A$2.76 millionN/A
6/27/2025Q1 2025
Exicure, Inc. stock logo
XCUR
Exicure
N/A-$0.45N/A$0.49N/AN/A
5/14/2025Q2 2025
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.34%N/A26.09%3 Years
Exicure, Inc. stock logo
XCUR
Exicure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.10
3.34
3.34
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
0.11
0.36
0.05
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Exicure, Inc. stock logo
XCUR
Exicure
N/A
2.91
2.91

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
70.52%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Exicure, Inc. stock logo
XCUR
Exicure
42.82%

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
9.10%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
4.57%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Exicure, Inc. stock logo
XCUR
Exicure
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
27099.99 million90.89 millionOptionable
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/A78.37 million74.79 millionN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Exicure, Inc. stock logo
XCUR
Exicure
506.32 million5.79 millionNot Optionable

Recent News About These Companies

Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 417.4%
Stocks to Watch: Exicure, TTEC
Exicure Shares Up After Swing to Profit in 1Q
Why Exicure Inc. (XCUR) Soared on Monday
Exicure announces issuance of new patent in Australia

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alector stock logo

Alector NASDAQ:ALEC

$1.56 +0.01 (+0.65%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$1.90 +0.34 (+21.79%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Citius Oncology stock logo

Citius Oncology NASDAQ:CTOR

$1.81 -0.25 (-12.14%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$1.87 +0.06 (+3.31%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$13.44 +0.15 (+1.13%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$14.43 +0.99 (+7.37%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Exicure stock logo

Exicure NASDAQ:XCUR

$7.40 -0.20 (-2.63%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$8.23 +0.83 (+11.22%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.